Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of…
- Trial name
- NCT01192880
- Testing
- Bitopertin, Antipsychotics
- Where
- 103 sites in United States, Bulgaria and 5 more
- Volunteers
- 625 people
- Sponsor
- Hoffmann-La Roche
Schizophrenic Disorders
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine…
- Trial name
- NCT00088491
- Testing
- Intramuscular Olanzapine Depot, Oral Olanzapine
- Where
- 4 sites in Finland, Turkey (Türkiye)
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Neurologic Disorders, Schizophrenia
Characterization of High-Level Cognitive Impairments in Patients With Neuropsychiatric Disorders
Neuropsychiatric disorders are extremely common, severe, and disabling conditions. In the field of psychiatry, they notably include schizophrenia, mood disorders (depressive and bipolar disorders), autism spectrum or…
- Conditions
- Neurologic Disorders, Schizophrenia, Bipolar Disorder (BD), Depressive Disorder
- Trial name
- COGPSY (NCT07295652)
- Testing
- Cognitive assessment, Brain MRI (optional), Electroencephalography (optional)
- Where
- 3 sites in France
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia; Psychosis, Cognitive Impairment
Efficacy of Computer-assisted Cognitive Remediation in Patients With Schizophrenia
Objective: To determine the efficacy of computer-assisted cognitive remediation (CACR) in patients with chronic schizophrenia in the community settings.
- Conditions
- Schizophrenia; Psychosis, Cognitive Impairment, Executive Function, Randomized Controlled Trial
- Trial name
- NCT04773171
- Testing
- Computer-assisted Cognitive Remediation, Conventional training programmes
- Where
- Hong Kong
- Volunteers
- 72 people
- Sponsor
- The Hong Kong Polytechnic University
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Add-On Therapy to Risperidonein Schizophrenia
These results suggest that the DA neuroprotection provided by DM in the inflammation-related neurodegenerative models is not mediated through the NMDA receptor.
- Trial name
- DM (NCT01189006)
- Testing
- Dextromethorphan
- Where
- Taiwan
- Volunteers
- 161 people
- Sponsor
- National Cheng-Kung University Hospital
Schizophrenia
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.
- Trial name
- NCT01451164
- Testing
- OPC-34712
- Where
- Japan
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl
- Trial name
- NCT01082250
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Sumitomo Pharma America, Inc.
22q11 Deletion Syndrome
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
The purpose of the present trial is to investigate the effects of omega-3 PUFAs in individuals aged 12-26 years with 22q11DS at ultra-high risk for developing a first episode of psychosis.
- Trial name
- NCT02070211
- Testing
- omega-3 PUFAs, Standard care
- Where
- Holy See
- Volunteers
- 80 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Schizophrenia, Bipolar Disorder
Dental Status of Patients With Severe Mental Illness
The investigators aim to assess the dental status of psychiatric patients suffering from severe mental illness (schizophrenia, bipolar disorder, ptsd, resistant depression).
- Conditions
- Schizophrenia, Bipolar Disorder, PTSD, Depression
- Trial name
- SMI-DENTAL (NCT01315509)
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Hadassah Medical Organization
Schizophrenia
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
- Trial name
- NCT00876304
- Testing
- PF-04802540
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Treatment-resistant Schizophrenia, Deep Brain Stimulation
Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia
The purpose of this project is to improve the clinical response and personal recovery of patients with treatment-resistant schizophrenia (TRS).
- Trial name
- DBS-R (NCT05337904)
- Testing
- On-Stimulation, Off-Stimulation
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
This randomized, multi-center double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235559
- Testing
- bitopertin [RO4917838] level 1, bitopertin [RO4917838] level 2
- Where
- 90 sites in United States, Bulgaria and 5 more
- Volunteers
- 604 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia Spectrum and Other Psychotic Disorders
Cognitive Behavior Therapy for Patients With Psychoses.
Patients with psychoses are randomized either to group treatment (ACT) or individual CBT for 18 sessions.
- Trial name
- NCT03501888
- Testing
- Cognitive Behavior Therapy, Acceptance and Commitment Therapy
- Volunteers
- 16 people
- Sponsor
- Karolinska Institutet
Schizophrenia and Related Disorders
An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study
This is an open-label extension study to continue to evaluate the safety, tolerability and efficacy of the Repetitive Transcranial Magnetic Stimulation (rTMS) in subjects with schizophrenia or schizoaffective disorder who…
- Trial name
- NCT05526833
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Substance Use Disorder, Attention Deficit Disorder With Hyperactivity
tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients
The purpose of this study is to study the efficacy and security of noninvasive brain stimulation as a new approach for patients with Substance Use Disorders (SUDs) plus other psychiatric conditions like ADHD, Schizophrenia…
- Conditions
- Substance Use Disorder, Attention Deficit Disorder With Hyperactivity, Bipolar Disorder, Schizophrenia
- Trial name
- tRND&SUDs (NCT01876524)
- Testing
- Transcranial Random Noise Stimulation
- Where
- Spain
- Volunteers
- 225 people
- Sponsor
- Spanish Foundation for Neurometrics Development
Schizophrenia, Exercise
Baduanjin Versus Brisk Walking for Cognition in Schizophrenia
The current study intends to recruit participants with schizophrenia for the practice of Baduanjin, brisk walking, and health education after enrollment. The study also including a maintenance program.
- Conditions
- Schizophrenia, Exercise, Condition
- Trial name
- NCT06226779
- Testing
- Baduanjin exercsie, Brisk walking, Health education
- Where
- Taiwan
- Volunteers
- 63 people
- Sponsor
- Chang Gung Memorial Hospital
Schizophrenia
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
This is a Phase 3b, 3-year, open-label, multi-center study in which patients with DSM-5 diagnosis of schizophrenia whose current medication(s) is not well tolerated and/or clinical symptoms are not well controlled will be…
- Trial name
- PENNANT (NCT05643170)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.